← Russell 3000 cross-section

ABSI Absci Corp

Trailing twelve months to 2026-06-30 · as filed 2026-08-11, not restated
Healthcare

Scale

Market cap
$1.6bn
Revenue TTM
$2m
Net income TTM
$-121m
Free cash flow
$-109m
Composite score
32.1
Sector rank
#1760

Valuation

P / E
EV / EBITDA
EV / sales
900.2
FCF yield
-6.78%
Earnings yield vs 10-yr
-12.27pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-7,756.4%
EBITDA margin
-7,373.8%
ROE
-49.2%
ROIC
-280.5%
Revenue growth
-62.3%

Insider activity, last 90 days

Net open-market
$0.15m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Our revenue to date has been generated primarily from drug creation activities conducted through these partnered programs. Since our inception, we have financed our operations primarily from private placements of our equity securities, convertible promissory notes, the sale of common stock in our initial public offering (IPO), subsequent follow-on offerings, the incurrence of other indebtedness and other financing activities, and to a lesser extent, revenue derived from our drug creation activities leveraging our Integrated Drug Creation platform. For the six months ended June 30, 2026, all of our revenue was generated by performing drug creation activities for our partnered programs. …Absci Corp, 10-Q, period ended 2026-06-30, filed 2026-08-11

Read the full passage →